News Sentiment

ARWR sentiment intelligence

Arrowhead Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 81.82 Week of 19 Jun 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+9.8% over one week, +9.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction 9.8% Price confirming higher
Trend fit Trend active 9.2% over four weeks
Fair value 148.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
simplywall.st 11
Market source 8
Business Wire 5
Sahm 2
TradingKey 2
Quiver Quantitative 2
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 39
Earnings 16
Regulatory and legal 1
Balance sheet 1
Analyst action 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stock Titan Direct company coverage

EU approves Arrowhead's REDEMPLO for rare fat disorder FCS

Arrowhead Pharmaceuticals has received marketing authorization from the European Commission (EC) for REDEMPLO (plozasiran) to treat Familial Chylomicronemia Syndrome (FCS) in adults. This is the first and only siRNA medicine authorized by the EC for FCS that does not require gene

Tone
Positive 75/100
Event
Market update
Published
22 Jun 2026 16:36
Source
Stock Titan
Business Wire Direct company coverage

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it will host a 2026 Summer Series of R&D webinars focusing on its RNA interference (RNAi) based medicines. Part I, scheduled for June 29, 2026, at 11:30 AM EDT, will highlight the company's cardiometabolic pipeline. The webinar w

Tone
Positive 72/100
Event
Market update
Published
19 Jun 2026 04:10
Source
Business Wire
Investing.com Direct company coverage

Arrowhead Pharmaceuticals stock hits 52-week high at $82.30

Arrowhead Pharmaceuticals Inc. (ARWR) stock reached a new 52-week high of $82.30, trading near its peak with a 394% increase over the past year and a market capitalization of $11.5 billion. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its

Tone
Positive 72/100
Event
Market update
Published
18 Jun 2026 15:39
Source
Investing.com
TradingKey Direct company coverage

Arrowhead Pharmaceuticals Inc

The TradingKey platform provides an overview of Arrowhead Pharmaceuticals Inc. (ARWR), including its stock quote, market capitalization, and P/E TTM. However, the article explicitly states that relevant data for revenue breakdown by business segments and regions has not yet been

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 05:09
Source
TradingKey
Stock Titan Direct company coverage

Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownership

Arrowhead Pharmaceuticals director Matthew Gregory Cohen has filed an initial Form 3 with the SEC, indicating he currently holds zero shares of the company's Common Stock. This filing serves as a baseline disclosure for him as a newly reported insider and does not represent a buy

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:09
Source
Stock Titan
Stock Titan Direct company coverage

Director Matthew Cohen granted 11,882 RSUs at Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals director Matthew Gregory Cohen was granted 11,882 Restricted Stock Units (RSUs) on June 15, 2026, at no cash cost. These RSUs will vest over three years, aligning his compensation with the company's long-term performance. Following this grant, Cohen dire

Tone
Neutral 50/100
Event
Balance sheet
Published
18 Jun 2026 02:09
Source
Stock Titan
TradingKey Direct company coverage

Arrowhead Pharmaceuticals Inc (ARWR) Financial Health: Profitability & Balance Sheet Analysis

Arrowhead Pharmaceuticals Inc (ARWR) currently holds a financial score of 6.99, ranking 171 out of 388 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company reported a significant year-over-year decrease of

Tone
Negative 30/100
Event
Market update
Published
16 Jun 2026 19:40
Source
TradingKey
Stock Titan Direct company coverage

A Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant

Arrowhead Pharmaceuticals, Inc. has appointed Dr. Matt Cohen, a veteran healthcare investor with over 25 years of experience, to its Board of Directors, effective June 12, 2026. Dr. Cohen will receive standard non-employee director compensation and a sign-on grant of restricted s

Tone
Positive 70/100
Event
Market update
Published
16 Jun 2026 19:39
Source
Stock Titan
Kavout Direct company coverage

Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout

Arrowhead Pharmaceuticals is nearing a critical juncture with Phase 3 data for plozasiran in severe hypertriglyceridemia (SHTG) expected in Q3 2026, which could significantly expand its market beyond familial chylomicronemia syndrome (FCS). The company boasts a strong financial p

Tone
Positive 76/100
Event
Market update
Published
16 Jun 2026 03:10
Source
Kavout
Stock Traders Daily Direct company coverage

Why (ARWR) Price Action Is Critical for Tactical Trading

This article analyzes Arrowhead Pharmaceuticals Inc. (ARWR) with a focus on tactical trading due to divergent sentiment across all horizons. It identifies a mid-channel oscillation pattern and presents three distinct AI-generated trading strategies: Long Position, Momentum Breako

Tone
Positive 60/100
Event
Market update
Published
13 Jun 2026 20:10
Source
Stock Traders Daily
Barchart Direct company coverage

Alpha-1 Antitrypsin Deficiency Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma, AstraZeneca, Sanofi

The Alpha-1 Antitrypsin Deficiency (AATD) market, valued at approximately USD 940 million in 2024 across the 7MM, is projected for significant growth by 2036. This expansion is driven by increasing adoption of approved treatments, advancements in gene therapy and RNA-editing, and

Tone
Positive 66/100
Event
Market update
Published
09 Jun 2026 11:40
Source
Barchart
TradingView Direct company coverage

Arrowhead Pharmaceuticals, Inc. Trade Ideas — XETR:HDP1

This article compiles several trading ideas and analyses for Arrowhead Pharmaceuticals, Inc. (XETR:HDP1, NASDAQ:ARWR). Contributors discuss various technical patterns such as flag patterns, stair-step patterns, "cup and handle" formations, and potential reversals, along with fund

Tone
Positive 72/100
Event
Market update
Published
07 Jun 2026 15:40
Source
TradingView
Market source Direct company coverage

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals is preparing to release topline data for plozasiran (SHASTA-3 and SHASTA-4 studies) in severe hypertriglyceridemia in the third quarter, expressing cautious optimism. The launch of REDEMPLO for familial chylomicronemia syndrome is gaining momentum, showi

Tone
Positive 72/100
Event
Earnings
Published
05 Jun 2026 18:09
Source
Market source
ChartMill Direct company coverage

ARWR News | ARROWHEAD PHARMACEUTICALS IN (NASDAQ:ARWR)

This article provides recent news and analysis for Arrowhead Pharmaceuticals (NASDAQ:ARWR), highlighting its stock performance, recent drug launches, and participation in industry events. It includes financial updates such as strong Q2 earnings, revenue beats, and a report of its

Tone
Positive 74/100
Event
Earnings
Published
05 Jun 2026 11:39
Source
ChartMill
Business Wire Direct company coverage

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals, Inc. announced its participation in two upcoming healthcare conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company will present in fireside chats at both events, w

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 09:10
Source
Business Wire
AlphaStreet Direct company coverage

Arrowhead Pharmaceuticals Drops 7.0% Amid Sector-Wide Selling

Arrowhead Pharmaceuticals (ARWR) saw its stock price drop by 7.0% on Tuesday, closing at $69.95, as the biotechnology sector experienced a broad selloff. This decline was part of a wider downdraft affecting several peer companies, indicating a sector-wide investor rotation rather

Tone
Negative 30/100
Event
Market update
Published
02 Jun 2026 14:39
Source
AlphaStreet
MSN Direct company coverage

Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum

Arrowhead Pharmaceuticals is anticipating Q3 data from its SHASTA trial. This comes as approvals for its drug REDEMPLO are gaining momentum. The company is focused on advancing its pipeline with these key developments.

Tone
Positive 74/100
Event
Market update
Published
01 Jun 2026 07:09
Source
MSN
Business Wire Direct company coverage

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Arrowhead Pharmaceuticals presented new interim results from a Phase 1/2a clinical trial of ARO-INHBE, an RNAi therapeutic for obesity and MASH, at EASL 2026. The data show that ARO-INHBE significantly reduced liver fat as both a monotherapy and in combination with low-dose tirze

Tone
Positive 71/100
Event
Earnings
Published
27 May 2026 18:09
Source
Business Wire
Business Wire Direct company coverage

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

Arrowhead Pharmaceuticals shared new clinical data for plozasiran at the 94th European Atherosclerosis Society Congress, demonstrating its potential use in patients with moderate-to-severe renal or moderate hepatic impairment without dose adjustment. The data also included a case

Tone
Positive 72/100
Event
Market update
Published
27 May 2026 06:10
Source
Business Wire